Do risk attitudes differ across domains and respondent types?

Medical Decision Making

Volumn 27, Issue 3, 2007, Pages 281-287

  Prosser, Lisa A ^a,b   Wittenberg, Eve ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD PILGRIM HEALTH CARE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Health; Patients; Risk attitude

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; HEALTH STATUS; HEALTH SURVEY; HIGH RISK BEHAVIOR; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MULTIPLE SCLEROSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; PATIENT ATTITUDE; SOCIOECONOMICS; STATISTICAL SIGNIFICANCE;

ADULT; ATTITUDE; DATA COLLECTION; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENTS; RISK;

EID: 34249085958     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X07300602     Document Type: Article

References (25)

1. Weber EU, Blais A., Betz NE A domain-specific risk-attitude scale: measuring risk perceptions and risk behaviors. J Behav Decis Making. 2002 ; 15: 263 - 90.
2. Baron J., Asch DA, Fagerlin A., et al. Effect of assessment method on the discrepancy between judgments of health disorders people have and do not have: a Web study. Med Decis Making. 2003 ; 23: 422 - 34.
3. Kahneman D., Tversky A. Prospect theory: an analysis of decision under risk. Econometrica. 1979 ; 47: 263 - 91.
4. Tversky A., Kahneman D. Advances in prospect theory: cumulative representation of uncertainty. J Risk Uncertainty. 1992 ; 5: 297 - 323.
5. Prosser LA, Kuntz KM, Bar-Or A., Weinstein MC Patient and community preferences for treatments and health states in multiple sclerosis. Mult Scler. 2003 ; 9: 311 - 9.
6. Sumner W., Nease RF, Littenberg B. Status report on automated utility assessment with U-Titer. Med Decis Making. 1993 ; 13: 390.
7. Raiffa H. Decision Analysis: Introductory Lectures on Choices under Uncertainty. Reading, MA: Addison-Wesley ; 1968.
8. Stiggelbout AM, Kiebert GM, Kievit M., Leer Jwh, Stoter G., deHaes Jcjm. Utility assessment in cancer patients: adjustment of time tradeoff scores for the utility of life years and comparison with standard gamble scores. Med Decis Making. 1994 ; 14: 82 - 90.
9. Miyamoto J., Eraker SA Parameter estimates for a QALY utility model. Med Decis Making. 1985 ; 5: 191 - 213.
10. Pliskin JS, Shepard DS, Weinstein MC Utility functions for life years and health status. Operations Res. 1980 ; 28: 206 - 24.
11. McNeil BJ, Weichselbaum R., Pauker SG Fallacy of the five-year survival in lung cancer. N Engl J Med. 1978 ; 299: 1397 - 401.
12. StataCorp. Stata Statistical Software: Release 5.0. College Station, TX: Stata Corporation ; 1997.
13. Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 ; 33: 1444 - 52.
14. Jacobs LD, Wende KE, Brownscheidle CM, et al. A profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium. Mult Scler. 1999 ; 5: 369 - 76.
15. Goodin DS, the Northern California MS Study Group. Survey of multiple sclerosis in Northern California. Mult Scler. 1999 ; 5: 78 - 88.
16. Schwartz CE, Vollmer T., Lee H., the North American Research Consortium on Multiple Sclerosis Outcomes Study Group. Reliability and validity of two self-report measures of impairment and disability for MS. Neurology. 1999 ; 52: 63 - 70.
17. 1998 USA Statistics in Brief-Law, Education, Communications, Transportation, Housing. Washington, DC: U.S. Census Bureau ; 2000.
18. MacCrimmon KR, Wehrung DA Characteristics of risk taking executives. Manage Sci. 1990 ; 36: 422 - 35.
19. Schoemaker PJ Determinants of risk-taking: behavioral and economic views. J Risk Uncertainty. 1993 ; 6: 49 - 73.
20. Dolan P. Whose preferences count? Med Decis Making. 1999 ; 19: 482 - 6.
21. Ubel PA, Loewenstein G., Jepson C. Whose quality of Life? A commentary exploring discrepancies between health state evaluations of patients and the general public. Qual Life Res. 2003 ; 12: 599 - 607.
22. Prosser LA, Kuntz KM, Bar-Or A., Weinstein M. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health. 2004 ; 7: 554 - 68.
23. Gaskin DJ, Kong J., Meropol NJ, Yabroff KR, Weaver C., Schulman KA Treatment choices by seriously ill patients: the health stock risk adjustment model. Med Decis Making. 1998 ; 18: 84 - 94.
24. Fischhoff B. Value elicitation: is there anything there ? Am Psychol. 1991 ; 46: 835 - 47.
25. Rosen AB, Tsai JS, Downs SM Variations in risk attitudes across race, gender, and education. Med Decis Making. 2003 ; 23: 511 - 7.